Furthermore, patients with a UGT1A1 promoter polymorphism are more likely to develop hyperbilirubinemia after treatment with the anti-retroviral protease inhibitor atazanavir [5]. The gene discussed is UGT1A1; the disease is Hyperbilirubinemia.